Immunotherapy for low-grade non-Hodgkin secondary lymphoma of the orbit

Archives of Ophthalmology

Volumn 120, Issue 9, 2002, Pages 1225-1227

  Esmaeli, Bita ^a   Murray, James L ^a   Ahmadi, M Amir ^a   Naderi, Aresu ^a   Singh, Sanjay ^a   Romaguera, Jorge ^a   White, Christine A ^a   McLaughlin, Peter ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; RITUXIMAB;

AGED; ARTICLE; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORBIT; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHATIC METASTASIS; LYMPHOMA, B-CELL; MALE; ORBITAL NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 0036734579     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Orbit: Lymphoid tumors
2. Lymphoid tumors of the ocular adnexa: Clinical correlation with the working formulation classification and immunoperoxidase staining of paraffin sections
3. Clinicopathologic and immunologic characteristics of non-Hodgkin's lymphoma presenting in the orbit: A report of eight cases
4. Orbital and adnexal involvement in systemic non-Hodgkin's lymphoma
5. Staging and therapy of orbital lymphomas
6. Radiotherapy is successful treatment for orbital lymphoma
7. A retrospective analysis of different modalities for treatment of primary orbital non-Hodgkin's lymphomas
8. Use of rituximab, the new FDA-approved antibody
9. Rituximab in indolent lymphoma: The single-agent pivotal trial
10. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
11. Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma
12. Ritux-imab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
13. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
14. IDEC-C2BS: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
15. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
16. The anti-tumor effect of monoclonal anti-CD20 antibody (Mab) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines
17. Radiolabeled antibody therapy of B-cell lymphomas
18. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
19. Orbital lymphoma: Radiotherapy outcome and complications
20. Radiation retinopathy after external-beam irradiation: Analysis of time-dose factors
21. Radiation dose to the lens and cataract formation
22. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodkin's lymphoma